-
SunTrust: Medivation M&A Chatter Highlights Value, Company's 'Unique' Industry Position
Wednesday, April 13, 2016 - 1:44pm | 623Read More...The M&A rumors continue to swirl around biotech firm Medivation Inc (NASDAQ: MDVN), and a SunTrust analyst has commented that the latest take-over chatter highlights the value of the company. A Bloomberg report said Medivation has rejected a take-out offer from Sanofi SA (ADR) (NYSE: SNY),...
-
Why Medivation Could Be 'The Next Big Biotech'
Wednesday, April 6, 2016 - 4:32pm | 466Read More...Medivation Inc (NASDAQ: MDVN) could become the next big biotech, according to SunTrust Robinson Humphrey which initiated the coverage of the stock with a Buy rating and said it could be valued at $62 (range $51-$71) in M&A. In a note, analyst Peter Lawson said the company has a $1 billion...
-
Illumina Creates Helix: Here's What It Is, And What It's Worth
Wednesday, August 19, 2015 - 9:44am | 347Read More...The New York Times on Tuesday discussed the creation of Helix, a new gene sequencing venture. The creation of the new company has the backing and support of Illumina, Inc. (NASDAQ: ILMN), along with the investment firms Warburg Pincus and Sutter Hill Ventures. According to the publication, the...
-
Mizuho Reiterates Buy On Exact Sciences, Expects Positive Outcomes On 2 Coming Decisions
Tuesday, July 21, 2015 - 11:14am | 246Read More...In a report published Tuesday, Mizuho analyst Peter Lawson reiterated a Buy rating and price target of $35 on EXACT Sciences Corporation (NASDAQ: EXAS). Two announcements, expected in the fall, are expected to drive Cologuard adoption further. The analyst expects the USPSTF draft guidance and...
-
Numerous Analysts Bullish On VWR Following Quiet Period Expiration
Tuesday, November 11, 2014 - 11:57am | 155Read More...On Tuesday , the analyst quiet period on shares of VWR Corp (NASDAQ: VWR) expired. Following the expiration, analysts at multiple firms initiated bullish coverage on the company. Goldman Sachs: Buy rating; $31 price target. Isaac Ro outlined three catalysts: Accelerating growth in...
-
UPDATE: Mizuho Securities Initiates Coverage On VWR On Multiple Positive Factors
Tuesday, November 11, 2014 - 9:49am | 134Read More...In a report published Tuesday, Mizuho Securities analyst Peter Lawson initiated coverage on VWR Corp (NASDAQ: VWR) with a Buy rating and $27.00 price target. In the report, Mizuho Securities noted, “We are initiating coverage of shares of VWR Corp (VWR) with a Buy rating and a 12-month price target...
-
Mizuho Securities Ponders How CMS Reimbursement Might Affect EXACT Sciences Corporation
Friday, October 10, 2014 - 11:15am | 120Read More...In a report published Friday, Mizuho Securities analyst Peter Lawson reiterated a Buy rating and $22.00 price target on EXACT Sciences Corporation (NASDAQ: EXAS). In the report, Mizuho Securities noted, “Last night CMS issued preliminary reimbursement of $502 for Cologuard, above the approximately...
-
UPDATE: Mizuho Securities USA Initiates Coverage On Epizyme Inc On Epigenetics Pure Play
Friday, September 12, 2014 - 9:39am | 114Read More...In a report published Friday, Mizuho Securities USA analyst Peter Lawson initiated coverage on Epizyme Inc (NASDAQ: EPZM) with a Buy rating and $35.00 price target. In the report, Mizuho Securities USA noted, “We are initiating coverage of shares of Epizyme with a Buy rating and a price target of $...
-
UPDATE: Mizuho Securities USA Initiates Coverage On NewLink Genetics Corp On Emerging Market Pure Play
Friday, September 12, 2014 - 9:33am | 106Read More...In a report published Friday, Mizuho Securities USA analyst Peter Lawson initiated coverage on NewLink Genetics Corp (NASDAQ: NLNK) with a Buy rating and $50.00 price target. In the report, Mizuho Securities USA noted, “We are initiating coverage of shares of NewLink Genetics with a Buy rating and...
-
CareDx's 3-Part Bull & 3-Part Bear Cases
Monday, August 11, 2014 - 8:35am | 231Read More...CareDx (NASDAQ: CDNA) was initiated on by four analysts with an average price target of $13.28 (33.5 percent upside). Mizuho has the highest expectations for CareDX, with a $15 price target. In its research report, Mizuho laid out three aspects of the bull and bear cases. Bull Case...
